Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide and 3BNC117 Combination for MDR HIV-1
NCT04560569Phase 2Unknown
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Peptides, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
A Phase 2 trial of albuvirtide, Teropavimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Frontier Biotechnologies Inc.. Status: unknown.
02
Drugs
albuvirtideTeropavimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04560569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560569.